Health Care Innovation
Commentary
Comprehensive Regulatory Reform From The Bottom Up: The Case Of 340B
Using the ruse of “price negotiation”, the proponents of the Build Back Better legislation are pushing an ill-fated drug price control plan. Patients will bear exceptionally large costs should their idea of government-directed prices become law. These costs will include lower health outcomes due to reduced access to innovative drugs. ...
Commentary
Misguided Govt Policies Mean Employer-Based Coverage Costs Soar
The cost of employer-based health insurance continues to reach new heights. According to a report out this month from the Kaiser Family Foundation, premiums for a family health plan have risen 47% since 2011, and during that same period, employee earnings rose by 31%, while overall inflation ticked up just 19%. What’s ...
Blog
Could Mark Cuban’s new pharmaceutical venture be a slam dunk?
By Wayne Winegarden and Celine Bookin Billionaire investor Mark Cuban’s pharmaceutical company, the Mark Cuban Cost Plus Drug Company, is hoping to disrupt the pharmaceutical benefit management (PBM) industry with a new venture that seeks to address some of the most criticized practices of the industry. These include PBMs pocketing rather ...
Commentary
Federal government misses opportunity with unlawful private sector vaccine mandates
Earlier this month, the Biden administration mandated that employees at businesses with more than 100 workers be vaccinated or undergo weekly COVID-19 testing starting at the beginning of next year. Just two days later, the U.S. Court of Appeals for the 5th Circuit halted the order in response to a ...
Blog
Inflation, Drug Price Controls, and President Biden’s Build Back Better Program
Inflation is worrying Americans, and for good reason. The latest inflation report, the Consumer Price Index (CPI) released on November 10th, showed that prices were 6.2 percent higher in October 2021 compared to October 2020. More troubling, this was the fifth month in a row where the annual growth in ...
Featured
NEW BRIEF: 340B Hospitals More Profitable, Provide Less Charity Care, Receive Unwarranted Subsidies
So-called 340B hospitals whose mission is to help the vulnerable are more profitable and provide less charity care, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute, a California-based, free-market think tank. Click to download “Profiting from 340B” “The ...
Health Care
NEW BRIEF: U.S. Patients Could Save Up to $5.8 Billion Through Competition from Humira and Enbrel Biosimilars
Policies that promote biosimilar competition have the potential to save U.S. patients up to $5.8 billion collectively if biosimilars to Humira and Enbrel grow in market share, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute, a California-based, free-market ...
Blog
Getting the Drug Spending Facts Right
In a typical rant, Senator Sanders claimed in a September 15th press release that “at a time when the drug companies are charging us by far the highest prices in the world, Congress must demand that Medicare negotiate prices with this extremely greedy and powerful industry.” The Senator clearly misunderstands ...
Featured
New PRI Series to Show How Flawed U.S. Health Insurance System Inflates Costs, Decreases Quality and Reduces Health Outcomes
Addressing the ongoing problems with the U.S. health insurance system, the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute today announced the release of the first paper in the Coverage Denied series, which will analyze and propose reforms to fix the problems in the current system ...
Commentary
Drug Price Controls Inflict Worse Harm Than Even Critics Recognize
It’s no secret that H.R. 3 — the Democrats’ plan to impose price controls on prescription drugs — would have devastating consequences for our healthcare sector. After all, artificially restricting the price of any product invariably leads to shortages, rationing, and a slowdown in both investment and innovation. A new ...
Comprehensive Regulatory Reform From The Bottom Up: The Case Of 340B
Using the ruse of “price negotiation”, the proponents of the Build Back Better legislation are pushing an ill-fated drug price control plan. Patients will bear exceptionally large costs should their idea of government-directed prices become law. These costs will include lower health outcomes due to reduced access to innovative drugs. ...
Misguided Govt Policies Mean Employer-Based Coverage Costs Soar
The cost of employer-based health insurance continues to reach new heights. According to a report out this month from the Kaiser Family Foundation, premiums for a family health plan have risen 47% since 2011, and during that same period, employee earnings rose by 31%, while overall inflation ticked up just 19%. What’s ...
Could Mark Cuban’s new pharmaceutical venture be a slam dunk?
By Wayne Winegarden and Celine Bookin Billionaire investor Mark Cuban’s pharmaceutical company, the Mark Cuban Cost Plus Drug Company, is hoping to disrupt the pharmaceutical benefit management (PBM) industry with a new venture that seeks to address some of the most criticized practices of the industry. These include PBMs pocketing rather ...
Federal government misses opportunity with unlawful private sector vaccine mandates
Earlier this month, the Biden administration mandated that employees at businesses with more than 100 workers be vaccinated or undergo weekly COVID-19 testing starting at the beginning of next year. Just two days later, the U.S. Court of Appeals for the 5th Circuit halted the order in response to a ...
Inflation, Drug Price Controls, and President Biden’s Build Back Better Program
Inflation is worrying Americans, and for good reason. The latest inflation report, the Consumer Price Index (CPI) released on November 10th, showed that prices were 6.2 percent higher in October 2021 compared to October 2020. More troubling, this was the fifth month in a row where the annual growth in ...
NEW BRIEF: 340B Hospitals More Profitable, Provide Less Charity Care, Receive Unwarranted Subsidies
So-called 340B hospitals whose mission is to help the vulnerable are more profitable and provide less charity care, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute, a California-based, free-market think tank. Click to download “Profiting from 340B” “The ...
NEW BRIEF: U.S. Patients Could Save Up to $5.8 Billion Through Competition from Humira and Enbrel Biosimilars
Policies that promote biosimilar competition have the potential to save U.S. patients up to $5.8 billion collectively if biosimilars to Humira and Enbrel grow in market share, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute, a California-based, free-market ...
Getting the Drug Spending Facts Right
In a typical rant, Senator Sanders claimed in a September 15th press release that “at a time when the drug companies are charging us by far the highest prices in the world, Congress must demand that Medicare negotiate prices with this extremely greedy and powerful industry.” The Senator clearly misunderstands ...
New PRI Series to Show How Flawed U.S. Health Insurance System Inflates Costs, Decreases Quality and Reduces Health Outcomes
Addressing the ongoing problems with the U.S. health insurance system, the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute today announced the release of the first paper in the Coverage Denied series, which will analyze and propose reforms to fix the problems in the current system ...
Drug Price Controls Inflict Worse Harm Than Even Critics Recognize
It’s no secret that H.R. 3 — the Democrats’ plan to impose price controls on prescription drugs — would have devastating consequences for our healthcare sector. After all, artificially restricting the price of any product invariably leads to shortages, rationing, and a slowdown in both investment and innovation. A new ...
